Utama › Limfoma Burkitt › Washington

Kajian klinikal Limfoma Burkitt di Washington

11 kajian untuk Limfoma Burkitt sedang mencari peserta di lokasi di Washington.

Bandar di Washington

Teks kajian rasmi (Bahasa Inggeris)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Seattle Children's Hospital, Seattle
Providence Sacred Heart Medical Center and Children's Hospital, Spokane
Mary Bridge Children's Hospital and Health Center, Tacoma

Mengambil pesertaFasa 2

366 Days – 46 Years · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Seattle Children's Hospital, Seattle
Providence Sacred Heart Medical Center and Children's Hospital, Spokane

Mengambil pesertaFasa 2

365 Days · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Fred Hutchinson Cancer Research Center, Seattle

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07648264

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Seattle Children's Hospital, Seattle
Providence Sacred Heart Medical Center and Children's Hospital, Spokane
Mary Bridge Children's Hospital and Health Center, Tacoma
dan 1 lagi

Mengambil pesertaFasa 2

Umur 1 hingga 30 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Seattle Children's Hospital, Seattle
Providence Sacred Heart Medical Center and Children's Hospital, Spokane
Mary Bridge Children's Hospital and Health Center, Tacoma

Mengambil pesertaFasa 3

365 Days – 25 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03959085

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

Fred Hutch/University of Washington Cancer Consortium, Seattle

Mengambil peserta

Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT06710418

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutch/University of Washington Cancer Consortium, Seattle

Mengambil pesertaFasa 2Sukarelawan sihat dialu-alukan

6 Months · Semua jantina · Dikemas kini 29 Mei 2026 · NCT04195633

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Fred Hutch/University of Washington Cancer Consortium, Seattle

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 23 Apr 2026 · NCT07097363

Study of SGR-1505 in Mature B-Cell Neoplasms

Fred Hutchinson Cancer Center, Seattle

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 13 Feb 2026 · NCT05544019

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Fred Hutchinson Cancer Research Center, Seattle

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 5 Nov 2025 · NCT04260022

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Fred Hutchinson Cancer Center, Seattle

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 15 Nov 2024 · NCT06034275

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.